Financials data is unavailable for this security.
Cash flow in CADView more
In 2023, Thiogenesis Therapeutics Corp increased its cash reserves by 14.21%, or 880.35k. Cash Flow from Financing totalled 4.12m or -- of revenues. In addition the company used 3.25m for operations while cash from investing was breakeven.
Cash flow per share | -0.1062 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.1045 |
---|---|
Tangible book value per share | 0.1045 |
More ▼